Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Evaluating the efficacy of Tocilizumab in hospitalized patients in the inflammatory phase of COVID-19. Randomization 2:1 (TCZ:standard of care).
Description: (assessed using 7-category ordinal scale) 7 death 6 in ICU with ECMO/ mechanical ventilation 5 in ICU, no ECMO/ mechanical ventilation 4 in hospital, not ICU, needs supplementary oxygen 3 in hospital, not ICU, no supplementary oxygen 2 not in hospital, but not back to normal 1 not in hospital, back to normal
Measure: Clinical status at day 28 Time: day 28Description: defined as a National Early Warning Score 2 (NEWS2) of>/=2 maintained for 24 hours
Measure: Time to clinical improvement Time: 28 daysDescription: relative on a 7-category ordinalscale of clinical status
Measure: Time to decline of at least 2 categories Time: 28 daysDescription: (mode and duration of respiratory support) Hospital day when respiratory support needed with non-invasive ventilation - and duration. Hospital day when respiratory support needed by invasive mechanical ventilation -and duration.
Measure: Incidence of mechanical and/or non-invasive ventilation Time: 28 daysDescription: days not in ventilator
Measure: Number of ventilator-free days to day 28 Time: 28 daysDescription: days without organ failure
Measure: Organ failure free days to day 28 Time: 28 daysDescription: ICU admission day
Measure: Incidence of ICU stay Time: 28 daysDescription: days on ICU
Measure: Duration of ICU stay Time: 28 daysDescription: time to death, mechanical ventilation, or ICU admission (whichever occurs first)
Measure: Time to clinical failure Time: 28 daysDescription: during ICU stay SAPS II = simplified acute physiology score II min 0 (best), max 163 (worst)
Measure: SAPS II Time: 28 daysDescription: during ICU stay CCI = Charlson Comorbidity Index min 0 (best), max 37 (worst)
Measure: CCI Time: 28 daysDescription: during ICU stay APACHE II = acute physiology and chronic health evaluation II min 0 (best), max 71 (worst)
Measure: APACHE II Time: 28 daysDescription: during ICU stay SOFA 6 = sequential organ failure assessment min 0 (best), max 24 (worst)
Measure: SOFA 6 Time: 28 daysDescription: during and end of period of 28 days
Measure: Mortality rate Time: 28 daysDescription: as evidenced by normal body temperature and respiratory rate and stable oxygen saturation on ambient air or Measure: Time to hospital discharge or "ready for discharge"
Time: 28 daysDescription: days on suppl oxygen
Measure: Duration of supplemental oxygen Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports